InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.19
(
0.07%
)
Bitcoin
64,153.41
(
0.24%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 109461

Wednesday, 11/24/2010 12:40:31 PM

Wednesday, November 24, 2010 12:40:31 PM

Post# of 251721
Unlike Lovenox, Copaxone does not have any “junk” that needs to be characterized (#msg-56267201), which makes Copaxone an easier task for MNTA to replicate, all told, than Lovenox was.

The FDA’s published guidance for what is required for approval of generic Copaxone will probably end up being taken from MNTA’s application, as was the case with Lovenox.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up